Subcutaneous RYBREVANT(amivantamab) delivers promising 45 percent overall response rate with median duration of response of 7.2 months in recurrent or metastatic head and neck cancer
Responses were rapid and durable, and tumour shrinkage was observed in 82…
Precede Biosciences Presents New ESMO 2025 Data Demonstrating Its Liquid Biopsy Platforms Ability to Resolve Target Expression and Molecular Subtypes in Small Cell Lung Cancer
Small cell lung cancer (SCLC) accounts for 15% of all lung cancers…
Lung Cancer Genetics Study Launches Open-Source Data Platform to Research Community
SAN FRANCISCO, Sept. 06, 2025 (GLOBE NEWSWIRE) -- 23andMe Research Institute, Troper…
HUTCHMED Highlights Clinical Data to be Presented at the 2025 World Conference of Lung Cancer and the CSCO Annual Meeting 2025
September 04, 2025 20:00 ET | Source: HUTCHMED (China) Limited HONG KONG…
Wheres the Commitment? Provincial Silence on Big Tobacco Payouts Leaves Canadians Wondering if Lung Health Will be Left Behind, Says National Lung Health Alliance
TORONTO, Aug. 28, 2025 (GLOBE NEWSWIRE) -- On Friday, August 29, the provinces…
Intas Pharmaceuticals Launches HETRONIFLY (Serplulimab), India’s First Novel Immunotherapy for Advanced Small Cell Lung Cancer
AHMEDABAD, India, Aug. 5, 2025 /PRNewswire/ -- Intas Pharmaceuticals has launched HETRONIFLY™…
Connect Biopharma Presents Data Supporting Rademikibart at the European Academy of Allergy and Clinical Immunology (EAACI) 2025 Annual Congress
– Rademikibart significantly improved lung function and asthma control in patients with…
MannKind to Highlight Data from Recent Pediatric and Adult Studiesof Inhaled Insulin (Afrezza) at American Diabetes Associations85th Scientific Sessions in Chicago, June 20-23
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., June 09, 2025 (GLOBE NEWSWIRE) --…
Roches Tecentriq combined with lurbinectedin shows significant survival benefit in extensive-stage small cell lung cancer
46% reduction in the risk of disease progression or death, and 27%…